- Nirvana Life Sciences (NIRV) has signed a letter of intent with Innovate Phytotechnologies Inc. (INVP)
- The LOI is for the development and distribution of the company’s psilocybin and psilocin based products
- The strategic relationship will begin with the production of 20g each of psilocybin and psilocin and will increase with market demands
- INVP is a company dedicated to being a leading service provider in the Health Canada-regulated space by offering a broad range of services
- Nirvana Life Sciences Inc. a life sciences company with the objective of researching and developing non-addictive pain management and relapse prevention products
- Shares of Nirvana Life Sciences Inc. are unchanged, trading at $0.47 per share at 09:53 am ET
Nirvana Life Sciences (NIRV) has signed a letter of intent with Innovate Phytotechnologies Inc. (INVP)
The LOI is for the development and distribution of the company’s psilocybin and psilocin based products.
The partnership will begin with the production of 20g each of psilocybin and psilocin and will increase with market demand.
“This is a major step for the company, the ability to develop and distribute unique products through a Health Canada licensed facility that has full analytical capabilities will allow Nirvana to offer the highest level of quality assurance,” noted Michael McCune, Nirvana’s Vice President of Operations.
“Working with Innovate through to development and distribution of our novel addictions focused formulations will ensure that each level of the supply chain can meet the rigorous standards set forth by Health Canada,” he added.
A biotechnology and wellness research centre, INVP is dedicated to being a leading service provider in the Health Canada-regulated space by offering a broad range of services.
These services include analytical testing, research and development (R&D), patentable intellectual property (IP) development and protection, genomic services, pharmaceutical product development which includes novel formulations, manufacturing and more.
Nirvana Life Sciences Inc. a life sciences company with the objective of researching and developing non-addictive pain management and relapse prevention products that mitigate the symptoms of chronic pain and support patients who battle with addiction.
Shares of Nirvana Life Sciences Inc. are unchanged, trading at $0.47 at 09:50 am ET.
